Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 222
- Registration Number
- NCT00003941
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels (Bruxelles), Belgium
🇩🇪St. Johannes Hospital - Medical Klinik II, Duisburg, Germany
🇩🇪Universitaetsklinikum Halle, Halle (Saale), Germany
Surgery With or Without Combination Chemotherapy in Treating Patients With Stomach Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 144
- Registration Number
- NCT00004099
- Locations
- 🇧🇪
Institut Jules Bordet, Brussels, Belgium
🇩🇪Universitaetsklinik Duesseldorf, Duesseldorf, Germany
🇩🇪Klinik & Poliklinik fur Strahlentherapie der Universitat zu Koln, Koln, Germany
Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 141
- Registration Number
- NCT00052312
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸Instituto Valenciano De Oncologia, Valencia, Spain
Chemotherapy With or Without Surgery in Treating Patients With Recurrent Ovarian Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 38
- Registration Number
- NCT00006356
- Locations
- 🇮🇹
Spedali Civili, Brescia, Italy
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 5
- Registration Number
- NCT00025298
- Locations
- 🇮🇹
Ospedale Santa Croce, Cuneo, Italy
🇧🇪U.Z. Gasthuisberg, Leuven, Belgium
🇮🇹Istituto Nazionale per lo Studio e la Cura dei Tumori, Naples, Italy
Combination Chemotherapy in Treating Patients With Advanced Stomach Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Registration Number
- NCT00004873
- Locations
- 🇨🇭
Hopital Cantonal Universitaire de Geneva, Geneva, Switzerland
Combination Chemotherapy in Treating Men With Germ Cell Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-03-06
- Target Recruit Count
- 498
- Registration Number
- NCT00003643
- Locations
- 🇩🇪
Klinikum der Stadt Mannheim, Mannheim, Germany
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇩🇰Aarhus Universitetshospital - Aarhus Sygehus, Aarhus, Denmark
Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00023998
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00042835
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT00003569
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.